Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Titration Efficacy of Controlled-Release vs Immediate-Release Oxycodone in Cancer Pain
NCT03176199Phase 4Completed
- Sponsor
- Mundipharma
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of oxycodone in cancer pain (2 arms), sponsored by Mundipharma. Primary endpoints: Change of NRS pain score at 14 days and Number of breakthrough pain episodes at 14 days. Started Sep 2016; status: completed.
02
Drugs
oxycodone
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT03176199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03176199.